<SEC-DOCUMENT>0001193125-13-041209.txt : 20130206
<SEC-HEADER>0001193125-13-041209.hdr.sgml : 20130206
<ACCEPTANCE-DATETIME>20130206163925
ACCESSION NUMBER:		0001193125-13-041209
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130206
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130206
DATE AS OF CHANGE:		20130206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		13578351

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d482073d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): February&nbsp;6, 2013 (February 6, 2013) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;8 &#151; Other Events </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;6, 2013, ARCA biopharma, Inc. announced
that the editorial &#147;Treatment of the Heart Failure Patient with Atrial Fibrillation: A Major Unmet Need&#148; was published in the journal JACC: Heart Failure. The press release is furnished as Exhibit 99.1 hereto, the contents of which are
incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Unmet Medical Need in Treatment of Heart Failure Patients with Atrial Fibrillation Highlighted in Articles in Inaugural Issue of JACC: Heart Failure&#148;
dated February 6, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: February&nbsp;6, 2013 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SVP and General Counsel</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX TO EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Unmet Medical Need in Treatment of Heart Failure Patients with Atrial Fibrillation Highlighted in Articles in Inaugural Issue of JACC: Heart
Failure.&#148;</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d482073dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g482073g97v11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and General Counsel </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2100 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>UNMET MEDICAL
NEED IN TREATMENT OF HEART FAILURE PATIENTS WITH </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ATRIAL FIBRILLATION HIGHLIGHTED IN ARTICLES IN INAUGURAL ISSUE
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OF JACC: HEART FAILURE </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>New
Meta-Analysis Suggests Currently Approved Beta-Blockers Have Little or No </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Beneficial Effects in Heart Failure Patients
with Atrial Fibrillation </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Editorial Cites Unmet Medical Therapy Need, Calls for Development of New Therapies </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><I>Broomfield, CO, February&nbsp;6, 2013</I><B></B> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing
genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases, today announced that the editorial &#147;Treatment of the Heart Failure Patient with Atrial Fibrillation: A Major Unmet Need&#148; was published
in the first edition of JACC: Heart Failure, a new journal of the American College of Cardiology (<U>http://heartfailure.onlinejacc.org/article.aspx?articleid=1568319</U>).<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The editorial, authored by ARCA&#146;s President and Chief Executive Officer, Dr.&nbsp;Michael Bristow, and Dr.&nbsp;Ryan Aleong of the University of Colorado, discusses the authors&#146; views that the
treatment of atrial fibrillation (&#147;AF&#148;) in heart failure (&#147;HF&#148;) patients with reduced left ventricular ejection fractions (&#147;HFREF&#148;) is a major unmet need in cardiovascular therapies and should be approached differently
from current treatments for HFREF patients with sinus rhythm. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The article is an accompanying editorial to &#147;Beta-Blockers and Outcome in
Heart Failure and Atrial Fibrillation: A Meta-Analysis,&#148; by Michiel Rienstra, MD, et al. (<U>http://heartfailure.onlinejacc.org/article.aspx?articleid=1568318</U>), in the same edition of JACC: Heart Failure, which examined the results of four
major Phase 3 HFREF trials of the four beta-blockers (carvedilol, metoprolol, bisoprolol and nebivolol) that are currently approved for the treatment of HF. The authors of the meta-analysis report conclude that the evidence indicates that the
evaluated beta-blockers provided little or no benefit to HFREF patients with AF in these trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Rienstra report did not include data
from the published Phase 3 clinical study of Gencaro (bucindolol hydrochloride) known as the Beta Blocker Evaluation of Survival Trial (&#147;BEST&#148;) (<U>http://www.ncbi.nlm.nih.gov/pubmed/23223178</U>). The Bristow/Aleong editorial comments
that the data from BEST appear to be different from the data for the drugs evaluated in the Rienstra study, because retrospective analyses of the data from BEST appear to show evidence of efficacy for Gencaro in HFREF patients with AF, and enhanced
efficacy for those HFREF patients with </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
AF who possess a common genetic variant in the cardiac beta-1 adrenergic receptor (AR), the primary drug target of beta-blockers for cardiovascular indications. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The editorial authors discuss several reasons why the data for Gencaro in HFREF patients with AF appear to be different from that for the beta-blockers
analyzed in the Rienstra paper, including Gencaro&#146;s unique mechanisms of action. The editorial also notes that the use of anti-arrhythmic drugs to treat AF in HFREF patients is problematic due to the high frequency of pro-arrhythmia and adverse
effects on left ventricular function associated with these drugs. The authors highlight the potential significance of the medical need represented by HFREF patients with AF, noting that the two diseases commonly occur together (19% of the HFREF
patients in the trials analyzed by Rienstra had AF and other reports have estimated up to 40% of HFREF patients have AF), and the evidence that AF worsens mortality in HFREF patients. The editorial concludes by stating: &#147;At a minimum, . . .
AF-HFREF treatment should be approached differently from that for SR-HFREF, via therapies uniquely suited to dealing with this important subpopulation.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As previously reported, ARCA believes that Gencaro has potential as a treatment for AF. A retrospective analysis of data from the BEST Trial shows that HFREF patients with the genetic variation in the
beta-1 AR that ARCA believes enhances response to Gencaro had a 74% reduction in the risk of AF compared to placebo (p = 0.0003). These same patients experienced a 38% reduction in the risk of all cause mortality (p &lt; 0.05) and statistically
significant improvements on other major clinical efficacy endpoints. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on these data ARCA recently announced its plans to conduct a Phase
3 clinical trial of approximately 620 patients comparing Gencaro to metoprolol CR/XL for the prevention of AF in HFREF patients, known as GENETIC-AF. The trial is planned to be genetically enriched by enrolling only those patients who possess the
cardiac beta-1 AR genotype 389 arginine homozygous, which in the BEST Trial was associated with an enhanced response to Gencaro in preventing atrial fibrillation. The Company estimates that this genotype is present in about 50% of the U.S.
population. The primary endpoint of GENETIC-AF is planned to be the combination endpoint of recurrent symptomatic AF and all-cause mortality. The clinical endpoints planned for GENETIC-AF also include secondary endpoints to assess rate control and
HF morbidity and mortality in patients who develop permanent AF. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA has created an adaptive design for GENETIC-AF, under which the Company
plans to initiate a Phase 2B study in approximately 200 HFREF patients. Depending on the results of the Phase 2B portion, the trial could then be expanded to a Phase 3 study by enrolling an estimated additional 420 patients. A secondary endpoint of
the proposed Phase 2B portion of the trial will be AF burden, defined as a patient&#146;s actual time in AF, regardless of symptoms. Under the Company&#146;s proposed design, all 200 patients in the Phase 2B portion of the trial will have AF burden
measured by continuous monitoring, either by previously implanted cardiac resynchronization or defibrillation devices, or newly or previously inserted implantable loop recorders. At the end of enrollment of the first 200 patients, the primary
endpoint of recurrent symptomatic AF and all-cause mortality, and the secondary endpoint of AF burden will be evaluated by the trial&#146;s Data and Safety Monitoring Board for evidence of an efficacy signal. If a sufficient efficacy signal is
detected and acceptable safety is observed, the trial would then </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
proceed to the Phase 3 portion and full enrollment. Commencement of GENETIC-AF is conditional on receipt of the necessary funding, which ARCA intends to secure through equity financing or a
strategic partnership. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first
genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with the Laboratory Corporation of America (LabCorp), under which LabCorp has developed a companion genetic test for Gencaro. For more information please visit
<U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release and the associated presentation may contain &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to, statements regarding the ability of genetic variations to predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, and the potential for Gencaro to be
the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those
projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the
Company&#146;s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to
the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without
limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2011 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g482073g97v11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482073g97v11.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X0MO17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P(#<N,``R,#$S.C`R.C`W(#`Q.C,U
M.C`W``````.@`0`#`````0`!``"@`@`$`````0```-2@`P`$`````0```$<`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```*00````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"L`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`.ZR[[;\E[)(96XM#0=-/;*E7C.<._<'GD#<A2W[9=)$
M>J_Z4Q](_NJUZX;DFDDM8P-TUDR-VL^Y8.#!CG*67,>.>3(8^K_"]/\`5CPQ
M;DB0`(BJ%M>VES?$:2?*>%;Z5D6.+Z+"7;1N:3J0.-J5[JWU.<#(:8#G3$D?
MR!]+^L@])(.99_4_BI1@C@YS#+$>$3/#,#:<:/S16D\6.5C9UUB_6'K;NF.Q
MF5:N<\/O``,4@[7_`-7U'.]CEM+CK\[IG4L3JMUV2QEV6?3Q&&=*\8_JW_;]
M_JW?]=6RU7L&N:]H<TRUPD$<$%9_67Y]&+9EXE[:Q167NJ?7O#MON^GN:YBJ
M?4[J0SNC5L<?TN*?1>.\-$U._P"VU<^L!CH>>?"BS_J2DII])NZSU/!&9]LK
MI]0N#&"G<!M<6>XFQN[=M1.C]9OR<S(Z;FL:S+QI.^N=CV@ANX!_N;])JQNC
M?6*KI7U=I??BY%E>ZP-N8UIK+B]Y:S?O]G[GO8M/ZN]->;[NN9%K+;L\;JVT
MG=6RMQ#MN\AOJ/\`:Q)3:ZQUMO3W5XU%9R<[(TIH!CRWV']Q3JP^K6,W96>:
M[#KLQZV!C?Y.Z]EUEBP>DO\`M7UWSGVZOQVV"L'MM->.W_P-RZ])3D8UO5L;
MJS,3-N;D8M];S1:&!CM["UWIV;?^#WK730"02-1PJ?6.H-Z;TS(S3J:F?HV_
MO//LI9_;M<UJ2FBSKI=]9'=.D?9BPUL,<W-_26>_^2W]#_QBVUP?5[L/&Z=T
M[(P\IM_4,!VZZ"27NL/K7/\`</H_:/\`H6+ML3)KR\:K)J,UW,:]OP<-R2G_
MT.NON=3GW\M(M<?."=P_Z*LC)Q;@WUFR6SM,G<``7:O_`#M[UI9O2L3-=OL!
M99QZC#!('9T[FJJ/JYB#_#7?>W_R"QAR7-XYSC$0RXI2,H\1\>+U1DV_>Q2B
M+)C("M&I=G5A@94-C0-`WM/TVN_?1>@ES\JY\>T,`)\R?]B-_P`W,0\VW?>W
M_P`@M#%Q:,6KTJ&[6\GN2?WG%28>4YJ7,0R9N&$,6HC$WQ'HB>7&(&,+)EW<
M+ZX_6+$Z=T^W"KR:V]0RHH8W<":A9#7Y-K1[F5TU/]3W+8Z<,&GIU#,.QC\2
MBL,KL:X.;M8-N[U&^W\WW*&:>G8UM;KL=K[LRQM32*PYSGQ#?4?_`":V_G_F
M(SVXF%AV14&8];7.=56R00=7Q36WW;OZJU6J\/TKK?3.B_7#/QSE4_L[-,MN
M:\&ICR?5K:]X]C=F^ZK^1[%T?UGZMTQGU?RYRZ0<G'?]G'J-)LW#8ST0#^DW
M._<6I5@]/])OIXU3:R!M;Z;6P#_(V^U+[!T]NP_9J1Z;=C#L;[6S.QFGM:DI
MYGZG7])ZG]6&](NOK?;8;FVX^]OJ`%[[&O;6?=[6EMK+-JI_5_K?_-KJ=_U<
MZU<VNIKM^-D/(:P;_=)GZ%.1]/\`X*_U:UV9Q<&D_:?0K:^II(L:P;@(]VPM
M&[Z*ACG"ZE17FBD.;:WV.M8-VR3MYW>QWTVI*>5ZQ5?TGK5?UKZ:W[=TV\?K
M;:#O(!`K?:S9_.,=L;9N_P!+7_+748'6.E]1QQD8655=41J6N$M_DV,^E6_^
M0]6JJJJ:Q52QM=;?HL8`UH^#6JG?T'HF18;;\#&ML/+W5,)/Q):DIS<KZU8U
MW6</HW2KZ[[K+=V9:R'UUU5M?;;7ZC3L]>S9L_X)5.I=>Z1U#ZP].Z:W,H.+
MBN=EY%GJ-V.M8-N)CMLG8ZQKW^N]G\A=-3B8F.STZ*:ZF$06L:&B/ZK0H?LW
MIWIBO[+3Z8T#/3;MT_D[4E(>MLP[NE9%&9=713<PL]6UP8T.(]CM[H^B[W+F
M?J#]9<%V!^RLO)97DTO/V</<&A];C[6U.<?>]MF_]'^YZ:[&['Q[V!E]3+6`
MAP:]H<`1]%T.0W8&"Z-V/48(<)8TZC5KN$E/_]'U5))))2DDDDE/-]8R;+>I
MVFJTU_L^KTJFU@&VS*R6[F4TAP=M_0^EOLV^QEGYGZ2Q6>HY.54.F=/^U"O,
MR',%[V@2YK`TWO$_Z1_Z-NUO^%_<98K;/^6+/Z)_-CZ/]*_-_G/^"1+?^4Z?
MZ/\`S;OI?TC_`*S_`,%_I$E.7UKJF0R_+JIL=4,.EGI-8/?;E9&YN(QO/J5U
M^G_-M_G/S_96B=8>^YW3^G9%HK%P-^=!``KH:VVQ_J3[&>OZ:O7?\J8_]&^B
M?I_TCA_\Q_(_>_ZXLO/C_G#;/V>?LU4?;9VQZEG]&CV?\9_A/4V?F)*6?FYS
MOJPSUG$YF>XX^,7PUQ;:]XI>^`W;MP_TST?`R?LCLRUV0;NFX6/4-X#?3WL:
M]]PQMGYC*?0]F]ZU,KFO^:Y=_/?U'_S?_HS_`('U%7Q?^11_1/YIW\U_1/SN
M/^`_?24Y^'U2_/ZO12,@-;6PWY%-9:6`O;^KXGJ-]UKF,WW9%F[TMZG3^T.H
M]3SFU9KZL/&<RH.K#)]5L6V5MWL?_--=Z=W^D5WI_P#/'^B?S-7]&^GQ_P"V
MW_<=6<3^;?\`S7\X_P#F?H_2/T_^%_TO\M)3A]7ZIE5]0O%&0YN/B5AEE=8;
MN?D7:8V'47[G?:'_`,YO_P`%5_GHG1<K*.7D-R\SUFX%#:LGZ.TW#])>]NP?
M1QV_HM[_`.=L]5:#OI#^B_TH<\_1_P#;[_OBEB_1R_Z-_.O_`)KCC_M7_P`/
M_IDE.37UI_4<_"IHR/39D'[0ZNLM.VAO\U78X;G.ORG['V,8[]7I71K,Z=_.
M4?T+^9=_1OI?3_P'_=?]_P#X5::2G__9_^T0(E!H;W1O<VAO<"`S+C``.$))
M300E```````0`````````````````````#A"24T#[0``````$`$L`````0`!
M`2P````!``$X0DE-!"8```````X`````````````/X```#A"24T$#0``````
M!````!XX0DE-!!D```````0````>.$))30/S```````)```````````!`#A"
M24T$"@```````0``.$))32<0```````*``$``````````3A"24T#]0``````
M2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!:
M````!@```````0`U`````0`M````!@```````3A"24T#^```````<```____
M_________________________P/H`````/__________________________
M__\#Z`````#_____________________________`^@`````____________
M_________________P/H```X0DE-!`@``````!`````!```"0````D``````
M.$))300>```````$`````#A"24T$&@`````#;0````8``````````````$<`
M``#4````'`!*`$$`0P!#`"T`2`!&`"``4`!2`%\`,@`@`#8`(``R`#``,0`S
M`"``1@!)`$X`00!,`"``,@`Q`````0`````````````````````````!````
M``````````#4````1P`````````````````````!````````````````````
M`````!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$`````
M``!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````````
M`$)T;VUL;VYG````1P````!29VAT;&]N9P```-0````&<VQI8V5S5FQ,<P``
M``%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P``````
M```'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E3W)I
M9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E5'EP
M90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````
M5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P```$<`
M````4F=H=&QO;F<```#4`````W5R;%1%6%0````!````````;G5L;%1%6%0`
M```!````````37-G951%6%0````!```````&86QT5&%G5$585`````$`````
M``YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$`````
M``EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A=6QT
M````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E9F%U
M;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E````
M`$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO;F<`
M````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T;&]N
M9P``````.$))3004```````$`````CA"24T$#``````*70````$```"`````
M*P```8```$"````*00`8``'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`*P"``P$B``(1`0,1`?_=``0`
M"/_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`[K+OMOR7LDAE;BT-!TT]LJ5>,YP[]P>>
M0-R%+?METD1ZK_I3'TC^ZK7KAN2:22UC`W363(W:S[E@X,&.<I9<QXYY,ACZ
MO\+T_P!6/#%N2)``B*H6U[:7-\1I)\IX5OI618XOHL)=M&YI.I`XVI7NK?4Y
MP,AI@.=,21_('TOZR#TD@YEG]3^*E&".#G,,L1X1,\,P-IQH_-%:3Q8Y6-G7
M6+]8>MNZ8[&95JYSP^\``Q2#M?\`U?4<[V.6TN.OSNF=2Q.JW79+&799]/$8
M9TKQC^K?]OW^K=_UU;+5>P:YKVAS3+7"01P05G]9?GT8MF7B7MK%%9>ZI]>\
M.V^[Z>YKF*I]3NI#.Z-6QQ_2XI]%X[PT34[_`+;5SZP&.AYY\*+/^I*2FGTF
M[K/4\$9GVRNGU"X,8*=P&UQ9[B;&[MVU$Z/UF_)S,CIN:QK,O&D[ZYV/:"&[
M@'^YOTFK&Z-]8JNE?5VE]^+D65[K`VYC6FLN+WEK-^_V?N>]BT_J[TUYONZY
MD6LMNSQNK;2=U;*W$.V[R&^H_P!K$E-KK'6V]/=7C45G)SLC2F@&/+?8?W%.
MK#ZM8S=E9YKL.NS'K8&-_D[KV766+!Z2_P"U?7?.?;J_';8*P>VTUX[?_`W+
MKTE.1C6]6QNK,Q,VYN1BWUO-%H8&.WL+7>G9M_X/>M=-`)!(U'"I]8Z@WIO3
M,C-.IJ9^C;^\\^REG]NUS6I*:+.NEWUD=TZ1]F+#6PQS<W])9[_Y+?T/_&+;
M7!]7NP\;IW3LC#RFW]0P';KH))>ZP^M<_P!P^C]H_P"A8NVQ,FO+QJLFHS7<
MQKV_!PW)*?_0ZZ^YU.??RTBUQ\X)W#_HJR,G%N#?6;);.TR=P`!=J_\`.WO6
MEF]*Q,UV^P%EG'J,,$@=G3N:JH^KF(/\-=][?_(+&')<WCG.,1#+BE(RCQ'Q
MXO5&3;][%*(LF,@*T:EV=6&!E0V-`T#>T_3:[]]%Z"7/RKGQ[0P`GS)_V(W_
M`#<Q#S;=][?_`""T,7%HQ:O2H;M;R>Y)_><5)AY3FI<Q#)FX80Q:B,3?$>B)
MY<8@8PLF7=POKC]8L3IW3[<*O)K;U#*BAC=P)J%D-?DVM'N9734_U/<MCIPP
M:>G4,P[&/Q**PRNQK@YNU@V[O4;[?S?<H9IZ=C6UNNQVONS+&U-(K#G.?$-]
M1_\`)K;^?^8C/;B86'9%09CUM<YU5;)!!U?%-;?=N_JK5:KP_2NM],Z+]<,_
M'.53^SLTRVYKP:F/)]6MKWCV-V;[JOY'L71_6?JW3&?5_+G+I!R<=_V<>HTF
MS<-C/1`/Z3<[]Q:E6#T_TF^GC5-K(&UOIM;`/\C;[4OL'3V[#]FI'IMV,.QO
MM;,[&:>UJ2GF?J=?TGJ?U8;TBZ^M]MAN;;C[V^H`7OL:]M9]WM:6VLLVJG]7
M^M_\VNIW_5SK5S:ZFNWXV0\AK!O]TF?H4Y'T_P#@K_5K79G%P:3]I]"MKZFD
MBQK!N`CW;"T;OHJ&.<+J5%>:*0YMK?8ZU@W;).WG=['?3:DIY7K%5_2>M5_6
MOIK?MW3;Q^MMH.\@$"M]K-G\XQVQMF[_`$M?\M=1@=8Z7U''&1A955U1&I:X
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M24\WUC)LMZG::K37^SZO2J;6`;;,K);N932'!VW]#Z6^S;[&6?F?I+%9ZCDY
M50Z9T_[4*\S(<P7O:!+FL#3>\3_I'_HV[6_X7]QEBML_Y8L_HG\V/H_TK\W^
M<_X)$M_Y3I_H_P#-N^E_2/\`K/\`P7^D24Y?6NJ9#+\NJFQU0PZ6>DU@]]N5
MD;FXC&\^I77Z?\VW^<_/]E:)UA[[G=/Z=D6BL7`WYT$`"NAK;;'^I/L9Z_IJ
M]=_RIC_T;Z)^G_2.'_S'\C][_KBR\^/^<-L_9Y^S51]MG;'J6?T:/9_QG^$]
M39^8DI9^;G.^K#/6<3F9[CCXQ?#7%MKWBE[X#=NW#_3/1\#)^R.S+79!NZ;A
M8]0W@-]/>QKWW#&V?F,I]#V;WK4RN:_YKEW\]_4?_-_^C/\`@?45?%_Y%']$
M_FG?S7]$_.X_X#]])3GX?5+\_J]%(R`UM;#?D4UEI8"]OZOB>HWW6N8S?=D6
M;O2WJ=/[0ZCU/.;5FOJP\9S*@ZL,GU6Q;96W>Q_\TUWIW?Z17>G_`,\?Z)_,
MU?T;Z?'_`+;?]QU9Q/YM_P#-?SC_`.9^C](_3_X7_2_RTE.'U?JF57U"\49#
MFX^)6&65UANY^1=IC8=1?N=]H?\`SF__``57^>B=%RLHY>0W+S/6;@4-JR?H
M[3</TE[V[!]'';^BWO\`YVSU5H.^D/Z+_2ASS]'_`-OO^^*6+]'+_HW\Z_\`
MFN./^U?_``_^F24Y-?6G]1S\*FC(]-F0?M#JZRT[:&_S5=CAN<Z_*?L?8QCO
MU>E=&LSIW\Y1_0OYEW]&^E]/_`?]U_W_`/A5II*?_]D`.$))300A``````!5
M`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#<`+@`P`````0`X0DE-
M!`8```````<`"`````$!`/_A$DAH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C`O`#P_>'!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53
M>DY48WIK8SED)S\^"CP_861O8F4M>&%P+69I;'1E<G,@97-C/2)#4B(_/@H\
M>#IX87!M971A('AM;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X.GAA<'1K/2=8
M35`@=&]O;&MI="`R+C@N,BTS,RP@9G)A;65W;W)K(#$N-2<^"CQR9&8Z4D1&
M('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M
M<WEN=&%X+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N<RYA9&]B92YC;VTO:5@O
M,2XP+R<^"@H@/')D9CI$97-C<FEP=&EO;B!A8F]U=#TG=75I9#HX,&-E-S=D
M9BTW,#DX+3$Q93(M.#!B92UE,C$Q938U-3`Q86$G"B`@>&UL;G,Z>&%P34T]
M)VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\G/@H@(#QX87!-33I$
M;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#IC-3%B,68V82TW,#9F
M+3$Q93(M.#!B92UE,C$Q938U-3`Q86$\+WAA<$U-.D1O8W5M96YT240^"B`\
M+W)D9CI$97-C<FEP=&EO;CX*"CPO<F1F.E)$1CX*/"]X.GAA<&UE=&$^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\
M/WAP86-K970@96YD/2=W)S\^_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"
M$```;6YT<E)'0B!865H@!\X``@`)``8`,0``86-S<$U31E0`````245#('-2
M1T(```````````````$``/;6``$`````TRU(4"`@````````````````````
M```````````````````````````````````````````18W!R=````5`````S
M9&5S8P```80```!L=W1P=````?`````48FMP=````@0````4<EA96@```A@`
M```49UA96@```BP````48EA96@```D`````49&UN9````E0```!P9&UD9```
M`L0```"(=G5E9````TP```"&=FEE=P```]0````D;'5M:0```_@````4;65A
M<P``!`P````D=&5C:```!#`````,<E120P``!#P```@,9U120P``!#P```@,
M8E120P``!#P```@,=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD``&1E<V,`````````$G-21T(@245#-C$Y-C8M
M,BXQ```````````````2<U)'0B!)14,V,3DV-BTR+C$`````````````````
M`````````````````````````````````````````````````%A96B``````
M``#S40`!`````1;,6%E:(`````````````````````!865H@````````;Z(`
M`#CU```#D%A96B````````!BF0``MX4``!C:6%E:(````````"2@```/A```
MML]D97-C`````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````````````
M`!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````````````````````````````
M````````````````````````````````9&5S8P`````````N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````
M```N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="`````````````````````````````&1E<V,`````````+%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`````````````
M`"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M``````````````````````````````````!V:65W```````3I/X`%%\N`!#/
M%``#[<P`!!,+``-<G@````%865H@``````!,"58`4````%<?YVUE87,`````
M`````0````````````````````````*/`````G-I9R``````0U)4(&-U<G8`
M```````$``````4`"@`/`!0`&0`>`",`*``M`#(`-P`[`$``10!*`$\`5`!9
M`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`
MRP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!10%,
M`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I`?(!
M^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"P0++
M`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#
MTP/@`^P#^00&!!,$(`0M!#L$2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$\`3^
M!0T%'`4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&
M:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('Y0?X
M"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)
MSPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O(
M"^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.
M$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^
M$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,3
M0Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F
M%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449
M:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<HQS,
M'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@
MF"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\
M)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ**(H
MU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!
M+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R
M*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D
M-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\
MI#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P
M0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(
M2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN
M3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5
M*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE
M7#5<AES672==>%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C
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MC&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/25
M7Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZN
MGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*H
MQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"
MLSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]
MC[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]
MR+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33
MQM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\I
MWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K
M<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*
M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X`#D%D;V)E`&1`````
M`?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M_\``$0@`1P#4`P$1``(1`0,1`?_=``0`&__$`:(````&`@,!````````````
M``<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+$``"
M`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,74G&!
M&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-T
MDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JD
MI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!
M`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B%C,)
ML23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%
MH[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G
M]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#
M`0`"$0,1`#\`W,OD1W9E-N9!-E[4K!1UGVPFS&1BLT\/GUI%1P$@K%(%4LY(
M)LPM;WR0^_[]\3FCD+>X_9WVMW3Z/=Q`)+^\CH9(_$U*EO%6H1](+2$@FC)0
M"F9K]M>1;/<[8[[N\.N#52-#P-.+'U'D/L/1.Z.3,Y*0S2Y*O)F)D+"MJ0SL
MQN2;2:1J/OF-R)R%S]S[=MNFX\P[DL,KEV)GFU/7)-`X`K^SY=31=26%FHC2
MUB[13X5Q3\NEC28>N]/^65Y:0@#5659U%K`:;2C^O^P]Y><M?=_>**));R_D
MD9006N)\DTH:^)Q/GT&[C=8<GPH@!Z*O^;J1/A,AK>`U5=Y8V=605=6#>/5K
M',AX&DG_`&'LXWCV`9DEM_J+Y95U`E;B>HI6OX^'G^73,.[0'2_AQZ33\*^?
MY=(VOI\O2ZS'7Y`@&X#5E5^F]B/\]Q;_`'KWB9[@>T'.7+:27>S\P;C+"E25
M-Q-6GR[_`"Z$EG>64Y"O;1`_Z5?\W1B>@N\<Q3YZAV7NJO-=B\B5H\55U+?Y
M30USM%%2TH>W[M/4,=(!L58DW/T]Y>?<9^^7SEM7.VR^SONGO+WO+5\PM[.>
M8_KVURS(D$&K&N*1CH`-&5F+:F^'J.O<3D*QEV^XWS:+<1W<?=(J_"Z`$LWR
M(&?F!2@Z/U[[E]8[]>]^Z]U[W[KW1$,O\T\'C/F/B_C*8<=_#:C$/3UV>DJ+
M20[LGQRYBDH5DU>%8XZ6&6"2,C5YRO(^A]U[H]_OW7NO>_=>Z)IWK\B>[^GZ
MW.U>#^,.6[(V7AJ<5O\`>G!;[BI9I*)(S)55-3ACM.M>C2D"L7_?D](O^;>_
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M_'N3H2JJ84QU?KI&<$@B<,4%["]O?NO="+5[C_F'TD`R:]?]#UD"--//@Z7<
MV;;)_:QJC104U6U$()ZR:["VA0I`_5?W[KW1:V_F==A;#[`PW6?<OQWJ]K;@
MRF:Q&(EJ)MT/BXJ:+)UT=`,E#35&`JQ6TWDE!4+*M_I<7]^Z]U<;[]U[KWOW
M7NB_?)[O*@^/'3>ZNRZJ*"JK<;!#1X.@GDTK6YO)3)1XV-T!$DE/'4S*\H6Q
M\:GD>_=>Z</CEW/C>_>G]G]G4$<5++GZ%SD\;&^ML9DJ:HFIJFED!]2%O$)%
M!YT2+[]U[H<??NO=>]^Z]U__T-I/N<?<=T;\C=@8X\Q$2/[5OX=0$*M^.>??
MS@?>$Y2;FG[Y'O*CQZK>+=8V(/`TMK;&0<>O677)DG@\C;`P'<83_P`??I_V
MIB**IEAIZQC1K,H\-0RD1Q-_8,Z!&_8;F[`%@;6%K^\U?:GD#;HXK6TNT,*,
MHTO0"F,%@!E3ZBI]!QZ#^\[A-&'DA&HCB/\`-\_ET86DV=!08Z.',R4N,K<3
ME::6!IY8PE?05<ADGFATJ[U`0P+H(%@K?X^\OMOY)L]ML(8MVDBM[NVN5*AB
M*21.:LR@`EJ:5IBE#\^HZFWB2XG=K17DAEB(-`>UEP`?3B:].V1VC0U9W!78
M>5,A4Y"M,.*B@MY%6JF-1-4V9(VC4(I3C@*Q]G>X\F6%XN^W>U%9IYY"L(7X
M@';4S9`I@%?0`GI);[M-%]##=@I&BU<GA@4`\_M^T=%\WAMZ+%S/1JXJ*R,$
M531>N"*73=H("JAY`B^ES;]0(%QS[Q6]R^1+2VCFL$'BW8'?2A4-YJII4TX$
MTPU:5&>I"V7='N%68C3$?AKQ(]3_`)/E\^@5@0T6Z\&\)>-OXUC#JY5HF%7#
MI93Z2I##C\@^^7_-_)C<N>ZG)>\V%8P=YM,K4%7$ZD$4`(((X]2.)A<;/?I(
M`?T'_,:3U<=0DM0T9)))I:<DGDDF%"23^23[^FG9V9]IVMG8ES;QDD\2="U/
M6&-P`)Y@.&L_X>I7LQZ:Z#;N'L?#=1]8;W[(S]4M'C-IX"MR<D[J'`J`@@H(
M_&7CU^:OFC2UQP??NO=:F_<Z=G;!W-U#\J=WRU,&;[SR5=W'2Q4LDHIZ"*'<
M%)7TU!"Q>.6*+(T$]TA9S^T;7M[]U[K;#Z7[$H^VNI^ONR:&2-X=X[4P^;E$
M6D)#755)'_$J4*DDJJ:3(++$1J-BEK^_=>Z$[W[KW2<W>0-J[C)^@PF2)_UA
M22GW[KW6K5_+'R,-7\Z=NP$Z[8_LUT#D,`\4,@5@"6LPOP?Q[]U[K:UDCCFC
MDBE19(I4:.2-U#))&ZE71U-PRLI((/U'OW7NM2/OVM'3O\P?,C8=1+C):+N3
M#5M%'0-X$I3N#<44&0QM/%0M%XZ9J:I>'QJ!Z&L1^/?NO=;98RD%/A?XUE'C
MQ]-3XPY/(R3%HXJ*"&E^ZJY)BX#)'31JQ:XN`O/OW7NM7?N[O#?'\PCY7;;Z
MBVO6Y&AZ_7=$>WMOX>GFF2GI\;BYWAW-O*LI8ZBJHZBL6`5,\<N@L:98U-K6
M'NO=;)7374&S>C>O<!UUL?'14.(PM-IEGT0_>Y2OE.NKR63JHX87K:RHD-O(
MX+"-52]E`]^Z]T*7OW7NB=?,SXT8_P"0G7<4N*QU*W9FR<A0;BV%DSX*6=LA
M05D-0<169'P2U4>)K-&N2-"`TD:'\>_=>Z-)M)<PFV-OKN!0F<7$4`RZ*YD"
MY$4T?W8$A)+@3WYN;^_=>Z4/OW7NJ3?YC4VY/D5V0_Q\V#6&3']*=;;G[F[&
M:A:8U4.5I\%6U6W\#41Q^2"HCR-,(&C5U#"64%3>WOW7ND!_)D[LBD?LOH_+
M5?CJ364V\=NTM2[M4R3_`&C8_/44"O,PCBH8<7%(R*HLSDGW[KW5^/OW7NO>
M_=>Z_]':-[=<GN_L)0T9T[AIPOD950,<9CN'<_I7_7/'OA3[BVT,GWJ_>XN%
M61]Z1=1H/^(MMBIP/M_;UEERM4<B\NFA_P!QSP_T[]#SU92U$D<*5=5M"LQ\
MA.NDRF6QXJG(%QXBDT5>GTX57"_X>\^_:2PF^DMENKC;);*G]G+-%K&,!2")
M1\@&I\NHXYHFC#NT4=TDX_$B-3\ZC3^9%>D=2;M.X=\Y1\G,33T&0J<;CJ62
M37%0XVDJ9(J:F@UD@)%$JKJY9[`DD^X^Y*YZ_KESAO>X;K=!XH;J2*)-6I88
MHY"J1KDX5:"O$T!)/1S=[2-MV:U2V3ODC5V:E"S,M23]IS3R\AT9:?,8''XF
MGK*"7Q5D0]3PN$9X])5X[K8VD0Z3^>>/>6DVZ;/9;;%<VL@6X5>(/$4R,9H1
MCJ-DM;R>Y>*9:QD^?K_L'I`=D4TIH2^,FVGCJ2>FIJKQ)DZ)<LS5$$=0QE^\
MEEK$?R2$60K?W&_N-:,VWL^WMML%N\2O02QB8ZE#FNLF0&I_"17H^Y>D'C@7
M"W4DJL170VC!(QI`7]O1,JJ71NC#1&:.0KFL869)5E1G^\B+$."5>P^OOEM[
MI6:?UJY<$F@LN[VI!4AO]%7%1\_YYZF^S%=KO&"D#P'%"*?A/EU<;C_^`%#_
M`-0=-_UI3WWGV;_DD;5_SS1?\<7K#VY_W(G_`-.W^$]3/9ETSU4?_,>WN_8>
M_?C[\-MOY1**N[3WK1[JWY5>=(Z6@V7M=9*E\?F?(-"4F:FE!758%HAS?W[K
MW4+^:;U%LG=OP^$FR*G!I7='U&#S&V\3C:JFDJ9,%`HVY48>F6%VD^UIJ/)"
MH*@6`I[_`(]^Z]T&O\DWY%+OSJO=71V4KS-E>M)VS&VZ4L&T[1RM6DU5+=F,
MEDS^691?BQL/I[]U[J\?W[KW28WJVG:&YV/T&!RI_P#5*;W[KW6FS\`>[MJ]
M._,K$;YWA!GZK`4,?8N/JTVUA,EN7+1ODA-#!/'AL5!55]3#$Z?N&-"4!O[]
MU[J\/M/^=!\9]N8ZMQG7%#O;>V^Y'&+QV#R.V<GLZ&ES-6XI*3^(U&XJ2!8X
M:>JE4RJ5!*@@>_=>Z#/XA_R^=^[[[BJ_EW\JY<)-F=R9ZJW[M[8>%K8<GCI<
MEEI'KJ#*9"LI9GA2BH6J/+34R%6214U7`(/NO=62?.C=];L7XE=Y[BQ[S1U4
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MS>-#25-#%C\&F;SDTB1TAKV22C5RK'2**RG4H%PYD`_P]YJ>SG.>W(NW0V6V
M"[WJ2@4R$&.M#4>%2M1_%K_+H#\T[3.Z3M/=F&R%2VG#?[U_DIT\;RZOR]5G
M<SNOKO*T.6II:FGDW!1!VIDIMPY*2HJ)X<&R^1:JBFG5Q&A"&-0!=K\$7-OL
MOS7L?.&]\Z>TU[!?[%<S^+=VP<QM#>3L\DGTU`PDA=]01>PQ@**M6HIM/,]E
M^[[/:>8[=X9E4B)Z:M42``&3AI8"E3FIKPZ?]M;1W>DD=?ORLCV[@L;7TM/D
M(7F>HKDJ71IZ:"II?V5BIF:/]UM1LMQ;GW)W)VP^X%R8KWGPC:MEMY46578M
M+J(U*ICP`IIWMJ.,4ST5;GN>T4:#8XS<WLB,5(%%IP)!S4YP*?GU%[8WE025
M%70Y3$4=/61*BT64PLBTM-4TP5#1SO$R2_=JU+I``9/Q[<]VN<MO1;JTO]KC
M6Z10(Y8#I1DH-#$$'6-%.!6GY=7Y7VB<)%-;W3F,GN205(.=0J*4[J^1Z*$F
M7$V[MO1+*W[F>Q5D!`U(:Z)?P38_DCWR]YZYH6ZYSY4LHV!8[S;#_JLM?VCJ
M:(K(Q[3?L5P+=_\`CIZO0QW_`!;Z#_J#I?\`K0GOZ*-F_P"2/M7_`#S1?\<7
MK!^Y_P!R;C_3M_A/6:IJ(:2GFJJB5(8*>-Y9I9'5(XXT4LS.[$*H`'U)]F73
M'6O+\5^IMG_S*_DA\G?D]VE#FLIUC@MQTO7/3)H<E4X[SX;&5&0(J:6NIRRK
M+BX8!'+X].MJ@$_3W[KW5@N6_E:_%/)8O(X\8;>*O6T-531O4;SRM5#%-/`\
M<,[T\NJ.802L'TD6)7W[KW6N%\4]^UWP4_F='KK/5-53[;I.R<YU+G(?.T"Y
M'`;E:KQVRJNH9VCC\0K,CCJQM:$67C\'W[KW6ZNK*ZJRL&5@&5E(*LI%PRD7
M!!!X/OW7NDKOM@NR]UL?H-O98\?X4,WOW7NM,S^4+7TV7_F,[9Q]9!%5P/BN
MWF,%5!%40LT<$A0F.42*64_0VN/?NO=6H_SI_A/0YKK^/Y1]5X"DQ^Y-A)%2
M]B8O`8N.EES>V9I%6FW`PH5C#UN`JE5.4U.E26+#1S[KW4K^27\ZH^TMEU'Q
MB[$SLU3OG8=$U;U_792K,T^>V;"T<;8=)ZBH>66KP*R(L,:AB:9&8GT^_=>Z
MN-^3W7=3VQ\>^X>OJ&*2?)[DV#N*EP]/$NN2IS=/02UV&ID7\FIRE+$G]?5Q
M[]U[K4@_D^=TP=+?.'&;(WG))ATWS39OJ_*-4LL"TNYJ&6MI\302I*5+M5[C
M1(%^A!8$`_3W[KW6ZK[]U[KWOW7NL%554]#2U-;5S1T])1T\U555$K:8H*>G
MC:6::1C^F.*-"Q/X`]^Z]TA.LNU>O^X]M/O'K3<V.W=ME,SF,",UB91/0RY/
M`ULF/RD$,PXD^VJXF4D<&WOW7NJI/YN?9N0W!C^DOACLNMJEWG\DM_;>IL[3
M43L)J7KW%YJ&IR.4<0MYVAI<CCXWD%@OB1B;CCW[KW0^X/\`E8_%3$X;%8Q\
M)NSRT./HZ:I>AWAE**EGJXJ>-*NJBI80D</W=0K2$`?5C[]U[JF?^<=\'MA_
M'79O6_;G46.S--@YLI7;;WR,GD:G+R0RSO1G;]7]Y4>L&KJ:MXBC$`>.X)O;
MW[KW5QW\J#Y%Q_(GX>[&KJRJFJ]T]<E>N=V3U=2*BLKLIAJ"AJX\I("3)'#6
M4]>$0,2286Y_I[KW5E7OW7NO_]/8W^7.(RFUN]MTUM;&\,.Y):3/8J<@B.:D
M--%1NB2CTZXY:-KB^I;BXY'OYQOOO<M\P<C_`'G>>=ZNH72WW>2.\MV%0KQ&
M-(J:N!(:%M0&0"*\1UF_[2WEINO(>U00L#);!HG'F&J6X>A##[>@AV]ON?'!
MU@JC"LR>.<H[*S1.;M'Z?5XI&4:A^2!?VW[9^[LUK'X:W)C?P]#"I!*X[3ZC
M'V="#=>7TG(+1`T-1CS]?M]#T/>'[B:EQ^%Q<50!3T^5BRU=H<(L\R2Q-`KC
M@DTD9D4'_:N/>8>Q^^$4&W[/M<-Y^DEPLTIK34U5T@_Z0:A^?4>7?)^N>[N6
MC[VC*+BM!0U_::'\NGK/=XR5F1W7YJC70[AJ*MI$UZC"JUGW-'-&+Z?.OC5"
MW^H9O9SS![]"6_YG62YK97CR5S6@$FI"/G@+7^$G/2.RY)$<&V%8Z3P*OEQ[
M:,#\LUIZ@=`!G^PYZR&.G:M\D,'D\*LQ=H-6IG6(F]D)8G3^FY_K[Q/]PO>-
MY+1[,WFI(P=%36E34A>-!4\!YYZD+;.6UB<RB&C-QQQ^9_S]8>IL5E-_=G[/
MPF,CDGEDSV+J:@P(SM2X^FKZ>6NK7"W*I3TQ+$_06]P#[3['S![N>]7(FQ[;
M!+++)NMO(Y`+&*".9#-,1_#&E7-?(=&7--U:\O<K[Q>W#JJB!U%<:G92%7[2
M<=;!%/$*>F@@U:A!!%%J/Y$4:IJ/^OI]_4-9V_TEI:VH:HBC5*^NE0*_G3KG
M](_B2224IJ8G]IKUKJ_S6_YL_3E/T9NWH[XR;U'9'9.^C6[7W#N/:%+EIL1L
M'&4DT:9,G-"D@@GSU1.!'`M*TRQB.3R%"4NIZIT./\F?Y)_%=/C)U/T!M+?N
M%Q7=)@K<MO'KK(4^1Q>XJS>&1BCJL]DZ:&MH:>')0U;TY?RQ/)PO-N+^Z]U<
MKO??&TNMMJYG>^^L]C]L;3V_3I5YK/920PT&-II)XJ5)JF55<I&9YT6]CRWO
MW7NM&/\`G"]N]%]K_+>'M3XN;M.^%R^WZ*??.[-M8S,QXU-[X'[#$XI\;7S8
MZF3(M2XC&PWFA+H)%(U7'OW7NM@KX%_SBOC=VOUMUMU]W1NZ'J7NZDQN%VA/
MA]TT.6I<7N[*TR08NAK-O9;[.>D=\E&(]<=1)#)Y]=ETZ2?=>Z-=\M?YBWQ(
M^/>"WWLO?';&(?LN':^2^QZWPM'E\SNO)5=9BWEH*2.EQV.JJ>D-8LR%9*B2
M*)0UV8#GW[KW6G3_`"W/DGM?XV_.'9'<_9U%GL?U\9=]8K-Y2##92MDP=%N^
M"H%/E9Z.FII*FHAHW"B1(E=_5P#;W[KW6\OT]\B?CA\P=F[I?IWL+;7;&U(Z
M5,'NR+%K6+]E#N"CJTBH<K092CHJRDDK:6&;2LD8/H/]/?NO=::'S]Z+[!_E
M@?-W`;XZ>ERF&V=FLX^_NF,G1>:.&GI?N2<WL$O1ZV,6.I:AJ(I(!)44K.X5
ME!/OW7NMD'XD_P`Y'XK=][8V7B.Q-WCJ+N3,C%X2OV;NW#YF@I,KN:<04;G;
MV9BQ\^%EI<ID6/VL,E1'4%64%`>/?NO=$G_FI?RGMX;JW34_+/X<4E3#V#%4
M8G-[JZXP$\.(FJ<AB(XVAWKLF4RTL=+G8_MHIYX%>/RR1M*@>:0@^Z]T)?P?
M_G.;,&&Q'2'SP&2Z&[RVZ!A%W%O/;V6P6"WE34Y6FQ]3/$]#]SC,O9"D\DD2
M4D@"RB4EG(]U[JW6M^9/Q+Q^&.?JODIT>N+$"U!EC[.V?45'B<74_P`/I\M+
MD=5A^GQ:A^1[]U[JA'^8Q_.>Q78&ULST%\$OXYV1D-VTM=MO>':>V\!G9Z3'
MT.1ADQM5AMJQK0)D9<E4?<@/4F*-$3A&;4;>Z]U87\;^]/CU_+U^#/QKVWW[
MO6AZVW-FNIL=O`;-K\=E)-UYC.UF-H\AN"@Q^"HJ&HKYZ^#)U8ADUH@61O60
M`2/=>ZI?Z!_F$=0=P?S5\K\H_D;DZWKKK3;FW\]M[I2NW!C,U+B-NQ_PJMVY
M15&66EH:U<?-F\/,T\S6\<=9+<M8:O?NO=;=.Q-^;/[-VIB-\[!W!C]T[2S\
M,T^'SV*D:6@R$,%3-1S24\C(C,L=33NAX'*GW[KW53G\VWY(?$?_`&6KN_X_
M=D=H81>V:K:5?D=F==T%+D<ON6??>,Q\F3V<):.@Q]6M#3G+-3EIY6C2-&U:
MN#[]U[K7C_E&_P`Q1?A3V+N':G:.%SC=,]IU&*EW/F*3%9.NK=HYC#4^0I\;
MF(*-:=GEQLO\3?[X1*TS)$FE'(L/=>ZVW/\`AQ'X4_Z*_P#37_LQ&PO]&/\`
M$_X)_>C[C(^'^,>+S?PO^'_P_P#BOW_CY\?@U>_=>Z__U-Y?N'H[8O=F&AQ6
M[J6I2HHFDDQF8QDZTF4Q\DB@-XIGBGAEB9E4E)8W6XX')O!WOA]WSVZ]_=B@
MV?G>QE%S;EC;W,#^'<0LPH=+%65E)`)1T9:C`R:B_E'G??.2[Q[K:)E,;T#Q
MN-2.!ZBH(/'((/5<N7_ET]A15TIPG8&VYL>97:F%90UT=7%$&/B6I9"D4TF@
M\E5"D_CWS*W/^[#Y_LMQFDY<]Q=M:P+G1XB3+(JU[0Y%%9J<2H`^0ZR&M/O"
M["\"B^V&X$]!72RE2?.G$@?;GY]1H_Y?7<,:A4WYM&PXN:3($VM8"XD'T'LP
MMO[O3WOMD*)[@;-2O\$Q/^'K;^_/*#FIV.ZK]J_YNN1_E^]PMPV^]H,/^H3(
MC\6_XZ_CVY-_=\^^4R%&]P=FS_0F_P`_6A[[\G@U_<EW_O2_YNN%-_+M[1FJ
M85KM_;4AIBX\\J4%?)(L8Y8(@87=@+`_0$W]D<?]V5[H7]Y`-V]PMJ%KJ[F"
M3$@<30>IX"O#SQT[)]X/EF.)S!L5T9*8&I0*]'WZ)^-&Q>CH'K\8E3EMVUM)
M]KDMPY"<RN82RNU-CJ9(X*>CIBRW)"&5KD,Y6P'0K[O'W3_;G[O<,VY;+%+=
M\YW$/ASWDSESHJ"8X4"HD2$BI(7Q&R&<K11!///N3OG.[K!=,L6TH^I(D%!7
M^)S4EC^>D<0`<]&.]Y2=1WT%%-T-T;1)(E)TSU121R32U,J4W7>T($DJ)VUS
MU$BQ8=%>:9^7<^ICR3[]U[J9A.H>G<1EZ+=FW.K^M,7GJ>(C'[EPFRMK4.7@
MAD4J11YBAQD5;%%(AL=$@!'OW7NEOFL'A=RXNLP>XL/B\_A<C$(<AA\UCZ3*
MXNNA#K((JS'UT,])51"1`VET87`/U'OW7N@\I>ANC:&".EHNF>J*.EA!$5-2
M]=[0IX(@S%V$<,6'2-`68DV`Y/OW7NO2=#]'33TE5-TSU1+4T%1'5T-1)UWM
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M::LI)#B"]/54\J!DD0AT8`@@CW[KW0I`!0%4`````"P`'```X``]^Z]T#O97
MQZZ-[A@JX>SNIM@[TDK813U%?G-L8FJS!A"E`D>;-*N7@"J;#1,MO?NO=%]I
M/Y:GP5H:J"LI_C5UR*BFE6:)I*"KG02(;J7BGK)(I5O]0RD'\CW[KW1E=L](
M=,[+C@BVEU/UOMM:8((&PNR=MXV9/'IT-YZ7&Q3-("H.HL6N+W]^Z]T];GZT
MZXWM68S([RZ_V3NW(86.:'#UVY]J8+/5F)AJ"IJ(L9596@JYZ".<H"ZQ,@:P
MO?W[KW3!/T5TA50R4]5TWU54T\JE)8)^O=HS0R*?JLD4F(9'4_T((]^Z]T(&
M$P6#VSBZ3![;PV*V_A:!&CH</A,=1XK%T4;R/*Z4F/H(:>DID>61F(1`"S$_
M4^_=>Z1F8Z<ZAW#G)MS[@ZKZWSFY:A!'4;AS&Q]L9/.3QA!&(YLM6XN>OE01
MJ%LTA%A;Z>_=>ZP?Z$>F/^?1=8?T_P"/!VI^?_(3[]U[J+_H#Z*_@_\`=[_0
MMU-_`/OOXG_`_P#1SL_^#_Q*VG^(?PS^#?9??:>/+H\EOS[]U[K_U=_CW[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW58'\Q'-Y[<.6Z-Z*V'NC.X+?':
MFYLC1+#C,I]EB9,#21T,M>V=@5%D<L[)]O()H@EI+WU<>Z]U8!UI+L^#:F-V
M[LK+T67Q6T*>#;3-1U?WAI9L;$L#4\\I>1C*NGDDF_\`4^_=>Z#GY$;5D[`V
MY@MCXSN&JZ@S^4W+CJK'9/&PPUF0S`QXFJY\.E%)6T+/%4Q1%M>L!2@-C]#[
MKW0W8:BEPN"Q6.K\G+DY\5BJ&CK,Q6Z8Y\A+14D4$^1JO44CEJGC,C\D`L>?
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M224M322E2MQ8`V%O?NO='(]^Z]TELYO?:.VIL=3Y[<6*QD^6KXL7C8*FJ035
MF1FT^*CAB36YGDUBP('U]^Z]T[Y7,8O!XVIS&8KZ7&XRC@:HJJZLE6&GAA12
M[.[N1_9'T^I_`]^Z]TR1;]V9/D,)BH=S8>7([CI)*_!4:5L33Y2DBT%YZ5`?
M6@\@M]"U^+^_=>Z=<WN#";;H7R>>RE%B:"-D1JJNG2"+7(X1$4L;N[,P``!/
MOW7NFZ3>^T(LW0;;DW'B%SV4I7K:#%&LB^\JJ6-=3S1Q`DZ0O/-C;GW[KW67
M"[PVMN.MRN.P.>QF6KL'.*;+4U#4I/+03D`^.<(38\_BXO[]U[I1DA068A54
M$LQ(```N22>``/?NO=)==[[1?<=-M&/<.*EW+64,V2I<-#5)-634-.SK/4JD
M1=1'$T;`W((M[]U[I4^_=>Z][]U[K__6W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=414NU:+YB?+3NGN_>NZJC:GQXZ+2/8@S%/DVQM)N2EQYJGJ
MQ3Y+[B$X>)JA?\KFC]=Q&O-^/=>Z,_\`RSM@+A<!WCV?A,36[;Z\[=['&5ZQ
MV]6LY:BV=@UR<&.KH5DTOX,G'DE969$+:.1[]U[H#L;L[%=Y_P`R+*S2[JK<
MSM_HVNR,^5SF2KXJ>FRN\JVG,N-ZYVS1_<G[9]K4KS-,L"WJHZ%Y7`L;>Z]T
M.'SR[#W5N?LGHOX>;+RF0P59WI7OEMX93%35%-DGZ^P5153Y^@H:JE:.>EDG
MBQC:V5K-&65AI)]^Z]T%_7HP\/\`,SV]L'IG$4F"V-TGT?5;,[)AP<,5)19&
MIDI<U6X6LS"T$4%+65SY/+4^N24.YF6Y.KW[KW4G^8[CT[2[C^-OQ[Q.?W&V
M2[$W-2_WKV_0YNOIL#C]HQ9"G4[AR>$@F%)D9!:H"O(C-%X;KS[]U[I/[#VC
MAL3_`#6$Q/4NW\?@]C["Z8CQ6_$VICZ7$8"CW1/C:]$BRM%B4@HUR>36)"#(
MFN0QEC]/?NO=*3^8F=R=Z=R?'_XD[%JY(Z_,9:3L/=]7$\@3;>/P;1)C,M4H
MK*-/CJYQ&_U60K_7W[KW3!NOH#;NV?G%\5]C];+D,AN':VVMX;\[=WQ)6U,F
MX:B%XOMJ/([CJS(\\KY>MK%CB5I'"1RZ!Z2WOW7NCI_(3NC/GL79WQFZSKXL
M1OOL+$U^>W5O9I/VNM.O,=%5S9?/'2R^',5T=&:6C9F3PRU"3`C2"/=>ZKUZ
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MUCAX`KJPO[KW02?RX,#MKLCL#NGY-4FW,1M.BW3EJ?!=8;3I8Z6&3&;+QM-]
MA/N:AIXQ'*M+N6M699)="B2>*4$E@UO=>ZM]]^Z]U[W[KW7_U]_CW[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]UX_0^_=>ZJ>ZZ^)OQ5VSL_<]3/\`)]=Z?'--
M]9[/9W:%7V=U_#U>FZ*VH1LQ0;NW3@DH*^K:EJ/&&H:G)B.-K:H[V]^Z]U9W
M1TNWJO:,=%MNIQM'MFIP;TN(K-NRT28REQ<U&T-/4XB:CU4"T\$+:HF2\8L#
M]/?NO=$&^+/QX^*W4/8FYLQM#N_#]N=H97<V:+097L;9^>S&#W!4+739FGI\
M#@)Z>5MQ_:BH$\M5%-6Q0B504C+CW[KW0P]\=3=8=A=N]29D]L475_R%VS0[
MH_T928[-[33>F8P62P>;QVXH<7M3<<&0J,YCZ2AK:J=Y(*5Q`\1=F`0^_=>Z
MR_%OK#X[]51[QP'46^MO=B;\FR]37=I[F.\MO[OW[69ZHEC:I_O6<-.7PX2;
M2(Z3P4\45@`FJY/NO=5[;1V3N7NG^85V]OS?&_LST5O3:.)H=M_'S`9:7:U!
MO+<^S2F0BSV8QVR]VTU=7Y;">1I7AK*:E*`EO6=)(]U[JR;XW]<])]91;YP7
M6N]L5V!OF7<7WO;^YIMU83<^^JW=<XG:/^^PQ,M\16)&9!#2O!3*BZM*?7W[
MKW05=@?'[I/=/</;^;?O7([8[W["ZPQFW)Z:AWQL^CW;UWL6BRM#619C:^WF
MI%S&+HJRI@CBDK*E)HW#:0P)Y]U[H1_CMU3U7U17[@Q.%[+':G;57BL(^]-S
M;DW1@\_V"^!I:=(=OPUU'C3#-BL$D#+X#X(UJ#I=VD<!O?NO=`7W)\:/CIOW
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MHAITS5"\VF&GR3OX`JV0,+^_=>Z.O\.^I?C]T_LB+;G2G8^&[2D;&TTM;NJF
MWEM[=V2JL,*RM6A6)]NS''4&"2O%0(DIXHX&J/*>9"Y]^Z]T<?W[KW7O?NO=
#?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
